A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough

Summary

This is a phase II study that will investigate the efficacy, safety and tolerability of HRS-2261 in subjects with refractory chronic cough using a double blind, placebo controlled, randomized study design.

Timeline

Start

2023-03-09

Primary completion

2024-03-05

Completion

2024-03-05

Drugs

Indications